19 trials in 63 locations
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma [...]
Locations: University College London Hospitals NHS Foundation Trust (PI: Heather Shaw), The Clatterbridge Cancer Centre - LIVERPOOL (PI: Joseph Sacco)
People who develop a type of skin cancer known as 'melanoma' are often treated with immunotherapy. The type of immunotherapy used for patients with melanoma is known as Immune Checkpoint Inhibitors (ICI). While ICI is very successful, it can lead to negative side effects that are known as 'immune related adverse events' (irAEs). These irAEs can affect any part of the body and can range in severity from mild symptoms to death.There has been [...]
Locations: ROYAL FREE HOSPITAL (PI: Amna Sheri), The Royal Marsden Hospital (LONDON) (PI: Kate Young)
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing [...]
Locations: The Christie NHS Foundation Trust (PI: Patricio Serra)
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab. [...]
Locations: Belfast City Hospital (PI: Bode Oladipo), University Hospital Southampton (PI: Mathew Wheater), Guys and St Thomas' NHS Foundation Trust (PI: Yin Wu), Sarah Cannon Research Institute (PI: Anja Williams)
This is a phase 3, randomised, controlled study of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma. [...]
Locations: Taunton and Somerset NHS Foundation Trust (PI: Clare Barlow), University Hospitals Bristol and Weston Clinical Trials Unit (PI: Christopher Herbert), Oxford University Hospitals NHS Foundation Trust (PI: Miranda Payne), The Royal Marsden Hospital (SURREY) (PI: James Larkin), The Beatson West of Scotland Cancer Centre (PI: Pavlina Spiliopoulou), ROYAL FREE HOSPITAL (PI: Alexandra Pender), East and North Hertfordshire NHS Trust (PI: Heather Shaw), Queen Elizabeth Hospital Birmingham (PI: Lalit Pallan), Sarah Cannon Research Institute (PI: Anja Williams), Norfolk and Norwich University Hospital (PI: Jenny Nobes), Addenbrookes Hospital (PI: Nicola Thompson), The Christie NHS Foundation Trust (PI: Paul Lorigan), The Royal Marsden Hospital (LONDON) (PI: James Larkin), The Clatterbridge Cancer Centre - Aintree (PI: Joseph Sacco), SOUTHEND HOSPITAL (PI: Parkar Rosemeen)
This is a Phase 3, multicentre, open-label, randomised, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomised to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period. [...]
Locations: University Hospital Birmingham (PI: Lalit Pallan), Freeman Hospital (PI: Manal Elgendy), Guys and St Thomas' NHS Foundation Trust (PI: Debra Josephs), Sarah Cannon Research Institute (PI: Anja Williams), The Beatson West of Scotland Cancer Centre (PI: Pavlina Spiliopoulou), The Royal Marsden Hospital (LONDON) (PI: Andrew Furness)
This clinical trial is a prospective, multicentre, open-label, randomised, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. [...]
Locations: University Hospital Southampton NHS Foundation Trust (PI: Ioannis Karydis), The Beatson West of Scotland Cancer Centre (PI: Pavlina Spiliopolou), The Christie NHS Foundation Trust (PI: Jonathan Lim), THE ROYAL MARSDEN HOSPITAL (LONDON) (PI: Andrew Furness), THE ROYAL MARSDEN HOSPITAL (SURREY) (PI: Andrew Furness), Addenbrookes Hospital (PI: Pippa Corrie), Oxford University Hospitals NHS Foundation Trust (PI: Miranda Payne), GUY'S HOSPITAL (PI: Debra Josephs (CI: Yin Wu))
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease [...]
Locations: Clatterbridge Cancer Centre (PI: Joseph Sacco (PI)), Beatson West of Scotland Cancer Centre (PI: Pavlina Spiliopoulou (PI)), Mount Vernon Cancer Centre (PI: Prof. Paul Nathan)
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer. [...]
Locations: Sherwood Forest Hospitals NHS Foundation Trust (PI: Mohammed Omar Farooq), Royal United Hospital Bath (PI: Tania Tillett), Royal Cornwall Hospital (PI: Toby Talbot), Bristol Haematology and Oncology Centre (PI: Helen Winter), Somerset NHS Foundation Trust (PI: Clare Barlow), Royal Surrey County Hospital (PI: Mazhar Ajaz), Poole Hospital (PI: Tom Geldart), Singleton Hospital (PI: Sing Yu Moorcraft), Nottingham University Hospitals NHS Trust (PI: Hester Franks), The Christie NHS Foundation Trust (PI: Colin Lindsay), Weston Park Hospital (Sheffield) (PI: Sarah Danson), Addenbrookes Hospital (Cambridge) (PI: Pippa Corrie), Velindre Cancer Centre (Cardiff) (PI: Ricky Frazer), Royal Devon and Exeter Hospital (PI: Kate Scatchard), The Queen Elizabeth Hospital King's Lynn (PI: Kamalram Thippu Jayaprakash), Western General Hospital (Edinburgh) (PI: Ewan Brown), , Royal Bournemouth Hospital (PI: Tom Geldart), University Hospital Southampton (PI: Matthew Wheater)
DyNAMIc is designed as a randomised, parallel arm proof-of-concept study to: 1. Test our hypothesis that tumours respond (measured by ctDNA mutant BRAF TAB level) to reintroduction of targeted therapy (following drug holiday) 2. Test the thresholds we have simulated based on our pre-clinical data are correct or whether they need refining based on response in participants examined prospectively. Participants with stage III un-resectable or stage IV BRAF mutant metastatic melanoma eligible for the [...]
Locations: The Royal Marsden Hospital (LONDON) (PI: Praveena Idaikkadar), Addenbrookes Hospital (PI: Brent O'Carrigan), Royal Preston Hospital (PI: Ruth Board), Nottingham University Hospitals NHS Trust (PI: Hester Franks), POOLE GENERAL HOSPITAL NHS TRUST (PI: Dr Bryony Eccles), Northern Centre for Cancer Care - Freeman Hospital (PI: Ruth Plummer), Guys and St Thomas' NHS Foundation Trust (PI: Amanda Fitzpatrick), Oxford University Hospitals NHS Foundation Trust (PI: Miranda Payne), Royal United Hospitals Bath (PI: Tania Tillett), Velindre University NHS Trust (PI: Satish Kumar), The Royal Marsden Hospital (SUTTON) (PI: Praveena Idaikkadar), The Clatterbridge Cancer Centre - LIVERPOOL (PI: Shobha Silva), University Hospital Southampton (PI: Matthew Wheater), The Christie NHS Foundation Trust (PI: Rebecca Lee)
EXCISE is a randomised, participant, clinician and assessor-blinded, placebo-controlled trial (with internal pilot) comparing oral flucloxacillin versus no antibiotic (placebo) in adult patients undergoing ulcerated skin cancer excision in NHS UK hospitals under local anaesthetic with planned wound closure. [...]
Locations: Norfolk and Norwich University Hospital (PI: Ava Lee), Brighton General Hospital (PI: Claudia DeGiovanni), West Suffolk Hospital (PI: Kun Sen Chen), Stoke Mandeville Hospital (PI: Ryan Kerstein), University Hospital of Wales (PI: Adam Gold), Royal United Hospitals Bath (PI: Peter Glen), Churchill Hospital (PI: Rubeta Matin), Northampton General Hospital (PI: Elizabeth Gruber), Morriston Hospital, SBUHB (PI: Thomas Dobbs), Walsall Manor Hospital (PI: Aaron Wernham), Victoria Hospital, NHS Fife (PI: Samuel Kent), The James Cook University Hospital (PI: Jaskiran Azad), Castle Hill Hospital (PI: Joshua Totty)
In this study we aim to investigate the nature of immune responses in human skin and in melanoma and to utilise these insights in order to explore potential novel treatment and clinical management avenues to benefit patients. T cells, B cells and other inflammatory and cytotoxic cells, such as monocytes and macrophages, found in the circulation and the tumour lesions of patients with melanoma will be investigated and compared with those from healthy volunteers.We [...]
Locations: Guy's and St Thomas' NHS Trust (PI: Sean Whittaker)
MANIFEST is an observational research study. It will involve patients who are receiving immunotherapy as part of their planned cancer treatment at NHS hospitals - the study will not change or interfere with the care they receive. The aim is to collect and analyse samples and data that may help us better understand why some people benefit from immunotherapy, while others do not, and why some experience side effects. [...]
Locations: The Christie NHS Foundation Trust (PI: Prof Samra Turajlic)
To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma [...]
Locations: Guys and St Thomas' NHS Foundation Trust (PI: Amanda Fitzpatrick), Sarah Cannon Research Institute (PI: Anja Williams), The Beatson West of Scotland Cancer Centre (PI: Pavlina Spiliopoulou), St Bartholomew's Hospital (PI: Sukaina Rashid), The Clatterbridge Cancer Centre NHS Foundation Trust (PI: Joseph Sacco), The Christie NHS Foundation Trust (PI: Patricio Serra-Bellver), St James' University Hospital (PI: Maria Marples), The Royal Marsden Hospital (London) (PI: Andrew Furness), The Royal Marsden Hospital (Surrey) (PI: Andrew Furness), Addenbrookes Hospital (PI: Pippa Corrie), Queen Elizabeth Hospital Birmingham (PI: Lalit Pallan), Mount Vernon Hospital (PI: Paul Nathan)
The advent of immune ICI has remarkably improved survival in advanced melanoma patients in the last decade. Long term responders following 2 years of treatment with immunotherapy go on to surveillance with frequent radiological imageing every 3-6 months up to 5-10 years. This not only exposes patients with a relatively low risk of recurrence to significant amounts of ionising radiation, but also increases the burden and cost on already stretched radiology departments. Therefore, this [...]
Locations: Cambridge University Hospitals NHS Trust (PI: Pippa Corrie), Velindre Cancer Centre (PI: Ricky Frazer), ROYAL FREE HOSPITAL (PI: Alexandra Pender), ST HELEN'S & KNOWSLEY HOSPITALS TRUST (PI: Nathan Hamnet), The Beatson West of Scotland Cancer Centre (PI: Pavlina Spiliopoulou), Weston Park Hospital (PI: Maria Gultiaeva), East and North Hertfordshire NHS Trust (PI: Heather Shaw), The Christie NHS Foundation Trust (PI: Rebecca Lee), Musgrove Park Hospital (PI: Claire Barlow), University Hospital Southampton (PI: Matthew Wheater), The Clatterbridge Cancer Centre - LIVERPOOL (PI: Shoba Silva), University Hospital Birmingham (PI: Lalit Pallan), Leicester Royal Infirmary (PI: Harriet Walter), Barts Health NHS Trust (PI: Sukaina Rashid), Belfast City Hospital (PI: Bode Oladipo), Royal United Hospitals Bath (PI: Lucy Dumas), The Royal Marsden Hospital (LONDON) (PI: Kate Young)
Despite the success of the immunotherapy era, surgery still plays an important role in treatment of patients with metastatic melanoma. The ability to accurately identify lymph node disease greatly influences the extent of surgical resection, yet there are limitations in current imaging modalities. This study aims to evaluate PSMA as a melanoma-specific, diagnostic biomarker for use in patients with palpable lymphadenopathy and oligometastatic melanoma, to be used in staging and determining surgical resection margins [...]
Locations: The Royal Marsden Hospital (LONDON) (PI: Myles Smith)
REACT is a pragmatic, randomised controlled, multicentre trial to guide initial therapy for immune checkpoint inhibitor-induced arthritis. [...]
Locations: New Cross Hospital (PI: Dr Sabrina Raizada), Nuffield Orthopaedic Centre (PI: Dr Shirish Dubey), Leeds Teaching Hospitals NHS Trust (PI: Kulveer Mankia), Royal United Hospitals Bath (PI: Andrew Allard), University Hospitals Coventry and Warwickshire NHS Trust (PI: Tim Blake), University Hospitals Plymouth NHS Trust (PI: Owen Moore), The Queen Alexandra Hospital (PI: Ernest Wong), Guys and St Thomas' NHS Foundation Trust (PI: Andrew Cope), Newcastle upon Tyne Hospitals NHS Foundation Trust (PI: Arthur Pratt), University Hospital Birmingham (PI: Benjamin Fisher), Leicester General Hospital (PI: Dr Veena Patel)
The Liverpool Ocular Oncology Biobank (OOB) works closely with local and regional hospitals to collect and store ocular biosamples, blood and associated clinical data from consenting patients for use in research relating to eye cancers and other eye diseases. By doing this, the biobank can build a valuable collection that will be used by research groups across the world to address key basic and clinical research questions necessary to improve the healthcare of future [...]
Locations: The Liverpool Ocular Oncology Centre (PI: Dr Helen Kalirai (Biobank Custodian))
THIS IS A PATIENT, SELF-REFERRAL, ONLINE STUDYPatients can sign up at the MyMelanoma website www.mymelanomastudy.orgThe MyMelanoma project aims to build the world’s biggest melanoma database which will support research into melanoma all over the world.There are currently many researchers all over the world working to make things better for melanoma patients, however they are mostly working on small studies. In order to make faster progress these researchers need more information, both more detailed and [...]
Locations: This is an online study; anyone in the UK can take part.
